I

Iovance Biotherapeutics
D

IOVA

7.43500
USD
0.06
(0.81%)
Market Open
Volume
138,848
EPS
-1
Div Yield
-
P/E
-5
Market Cap
2,262,997,366
Related Instruments
    A
    ADPT
    -0.02000
    (-0.31%)
    6.39000 USD
    A
    ALLO
    0.05000
    (2.67%)
    1.92000 USD
    A
    ASTS
    -0.420
    (-1.83%)
    22.470 USD
    B
    BCEL
    0
    (0%)
    0.000000 USD
    C
    CRSP
    -0.420
    (-1.03%)
    40.300 USD
    F
    FATE
    -0.04000
    (-2.37%)
    1.65000 USD
    MRNA
    MRNA
    0.230
    (0.58%)
    39.590 USD
    S
    SLDB
    -0.03000
    (-0.72%)
    4.12000 USD
    More
News

Title: Iovance Biotherapeutics

Sector: Healthcare
Industry: Biotechnology
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.